Rucaparib for Advanced BRCA–Mutated Ovarian Cancer Granted FDA Priority Review

Rucaparib for Advanced BRCA–Mutated Ovarian Cancer Granted FDA Priority Review
The US Food and Drug Administration (FDA) has recently granted priority review to Rucaparib for the treatment of patients with advanced ovarian cancer who have germline or somatic BRCA–mutated tumors. Rucaparib was granted FDA’a Breakthrough Therapy Designation for this indication in April 2015. The therapy by Clovis Oncology is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *